Clinical Trial Detail

NCT ID NCT02616640
Title A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celgene Corporation
Indications

multiple myeloma

Therapies

Pomalidomide

Dexamethasone

Durvalumab

Age Groups: adult

No variant requirements are available.